The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Open accessAbstract
Objectives: The Blueprint (BP) Programmed Death Ligand 1 (PD‐L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD‐L1 immunohistochemistry assays. The goal of BP phase 2 (BP2) was to validate the results obtained in BP phase 1 by using real‐world clinical lung cancer samples. Methods: BP2 were conducted using 81 lung cancer specimens of various histological and sample types, stained with all five trial‐validated PD‐L1 assays (22C3, 28‐8, SP142, SP263, and 73‐10); the slides were evaluated by an international panel of pathologists. BP2 also assessed the reliability of PD‐L1 scoring by using digital images, and samples prepared for cytological examination. PD‐L1 expression was assessed for percentage (tumor proportional score) of tumor cell (TC) and immune cell areas showing PD‐L1 staining, with TCs scored continuously or categorically with the cutoffs used in checkpoint inhibitor trials. Results: The BP2 results showed highly comparable staining by the 22C3, 28‐8 and SP263 assays; less sensitivity with the SP142 assay; and higher sensitivity with the 73‐10 assay to detect PD‐L1 expression on TCs. Glass slide and digital image scorings were highly concordant (Pearson correlation >0.96). There was very strong reliability among pathologists in TC PD‐L1 scoring with all assays (overall intraclass correlation coefficient [ICC] = 0.86–0.93), poor reliability in IC PD‐L1 scoring (overall ICC = 0.18–0.19), and good agreement in assessing PD‐L1 status on cytological cell block materials (ICC = 0.78–0.85). Conclusion: BP2 consolidates the analytical evidence for interchangeability of the 22C3, 28‐8, and SP263 assays and lower sensitivity of the SP142 assay for determining tumor proportion score on TCs and demonstrates greater sensitivity of the 73‐10 assay compared with that of the other assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
A guideline of selecting and reporting intraclass correlation coefficients for reliability research
Koo, T. K., & Li, M. Y. (2016) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2016.02.012 · Cited by 31,709
Interrater reliability: The kappa statistic
McHugh, M. L. (2012) · Biochemia Medica · doi:10.11613/bm.2012.031 · Cited by 19,877
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Self-citationRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
Self-citationPD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Self-citationBüttner, R., Gosney, J. R., Skov, B. G., Adam, J., Motoi, N., Bloom, K. J., Dietel, M., Longshore, J. W., López-Ríos, F., Penault-Llorca, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7642 · Cited by 397
Self-citationHarmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Scheel, A. H., Dietel, M., Heukamp, L. C., Jöhrens, K., Kirchner, T., Reu, S., Rüschoff, J., Schildhaus, H.-U., Schirmacher, P., Tiemann, M., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.117 · Cited by 347
Ratcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
PD-L1 expression in small cell neuroendocrine carcinomas
Schultheis, A. M., Scheel, A. H., Ozretić, L., George, J., Thomas, R. K., Hagemann, T., Zander, T., Wolf, J., & Buettner, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.006 · Cited by 237
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000422 · Cited by 182
Self-citationComparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Hendry, S. A., Byrne, D. J., Wright, G. M., Young, R. J., Sturrock, S., Cooper, W. A., & Fox, S. B. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.112 · Cited by 162
Skov, B. G., & Skov, T. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000540 · Cited by 155
Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C. F., Lu, X. J. D., Gao, D., Ellison, K. E., Kowalewski, A. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.002 · Cited by 145
Self-citationImmune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31105 · Cited by 131
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
Sakakibara, R., Inamura, K., Tambo, Y., Ninomiya, H., Kitazono, S., Yanagitani, N., Horiike, A., Ohyanagi, F., Matsuura, Y., Nakao, M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.002 · Cited by 130
Russell-Goldman, E. E., Kravets, S., Dahlberg, S. E., Sholl, L. M., & Vivero, M. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21973 · Cited by 93
Ilié, M., Juco, J. W., Huang, L., Hofman, V., Khambata‐Ford, S., & Hofman, P. M. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21977 · Cited by 89
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., McLeod, D., & Hirsh, V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8049 · Cited by 84
Fujimoto, D., Sato, Y., Uehara, K., Ishida, K., Fukuoka, J., Morimoto, T., Kawachi, H., Mori, R., Ito, M., Teraoka, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.123 · Cited by 61
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Self-citationFelip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Self-citation
Metadata
- Authors
- Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., Chung, J.-H., Dacic, S., Lantuejoul, S., Mino-Kenudson, M., Moreira, A. L., Nicholson, A. G., Noguchi, M., Pelosi, G., Poleri, C., Russell, P. A., Sauter, J., Thunnissen, E., Wistuba, I., Yu, H., Wynes, M. W., Pintilie, M., Yatabe, Y., & Hirsch, F. R.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 13
- Issue
- 9
- Pages
- 1302-1311
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2804957255
- Cited by
- 794
- References
- 22
- FWCI
- 36.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- IHC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.